半乳糖凝集素-3在心脏疾病中的表达及其临床意义

摘要/Abstract

摘要： 半乳糖凝集素-3（galectin-3,Gal-3）作为一种可溶性β-半乳糖苷结合凝集素,其血清水平在心力衰竭（heart failure,HF）患者中显著升高,因而被广泛研究,而最近发现Gal-3在心衰的发生、发展及预后方面有着很强的预测作用,尤其是射血分数保留性心衰患者中。心力衰竭作为各种心血管疾病的终末阶段,即使目前已有较多针对心衰的治疗方案,但其再住院率及死亡率仍居高不下,且已逐渐成为我国公共卫生负担之一。而射血分数保留性心衰具有独特的病理生理基础,其早期很容易被忽略,所以需要独特的诊断和治疗方法,Gal-3可能作为一种敏感的生物学指标来显著提高诊断效率。并且在近期的研究中发现,Gal-3在其他的心血管疾病中,如心律失常、急性冠脉综合征、高血压等,也有着不同程度的表达,其血清水平也有着不同的意义。本文就Gal-3在心脏疾病中的发生发展及预测预后做一综述。

关键词: 半乳糖凝集素-3, 心肌纤维化, 心力衰竭, 心房颤动, 心室重塑

刘芝达, 方敏, 赵祖琴, 李雪峰. 半乳糖凝集素-3在心脏疾病中的表达及其临床意义[J]. 心血管病防治知识, 2022, 12(23): 91-94.

参考文献

[1] Lloyd-Jones DM, Larson MG, Leip EP,et al. Framingham Heart Study(2002):Lifetime risk for developing congestive heart failure: the Framingham Heart Study[J]. Circulation 106(24):3068-3072.
[2] Lloyd-Jones DM, Adams RJ, Brown TM, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association[J]. Circulation,2010,(121):e46-e215.
[3] 顾东风,黄广勇,吴锡桂,等.中国心力衰竭流行病学调查及其患病率[J].中华心血管病杂志,2003(1):6-9.
[4] Erdogan O, Karaayvaz E, Erdogan T, et al. A new biomarker that predicts ventricular arrhythmia in patients with ischemic dilated cardiomyopathy: Galectin-3[J]. Rev Port Cardiol (Engl Ed), 2021,40(11):829-835.
[5] Erdogan O, Karaayvaz E, Erdogan T, et al. A new biomarker that predicts ventricular arrhythmia in patients with ischemic dilated cardiomyopathy: Galectin-3[J]. Rev Port Cardiol,2021,40(11):829-835.
[6] Sundblad V, Croci DO, Rabinovich GA. Regulated expression of galectin-3, a multifunctional glycan-binding protein, in haematopoietic and non-haematopoietic tissues[J]. Histol Histopathol,2011,(26):247-265.
[7] Larsen L, Chen HY, Saegusa J, et al. Galectin-3 and the skin[J]. J Dermatol Sci,2011,(64):85-91.
[8] Li M, Guo K, Huang X, et al. Association Between Serum Galectin-3 Levels and Coronary Stenosis Severity in Patients With Coronary Artery Disease[J]. Front Cardiovasc Med,2022,9:818162.
[9] Sygitowicz G, Maciejak-Jastrzebska A, Sitkiewicz D The Diagnostic and Therapeutic Potential ofGalectin-3 in Cardiovascular Diseases[J]. Biomolecules. 2021,12(1):46.
[10] Suthahar N, Meijers WC, Silljé HHW, et al. Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update[J]. Theranostics, 2018,8(3):593-609.
[11] Liu X, Gu Y, Liu Y, et al. Ticagrelor attenuates myocardial ischaemia-reperfusion injury possibly through downregulating Galectin-3 expression in the infarct area of rats[J]. Br J Clin Pharmacol, 2018,84:1180-1186.
[12] Chen X, Lin J, Hu T, et al. Galectin-3 exacerbates ox-LDL-mediated endothelial injury by inducing inflammation via integrinβ1-RhoA-JNK signaling activation[J]. J Cell Physiol, 2019,234:10990-11000.
[13] Liu YH, D'Ambrosio M, Liao TD, et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced bygalectin-3, a mammalian adhesion/growth-regulatory lectin[J]. Am J Physiol Heart Circ Physiol. 2009,296(2):H404-412.
[14] Grübler MR, Delgado G, Kleber M, et al. Effect of Galectin 3 on Aldosterone-Associated Risk of Cardiovascular Mortality in Patients Undergoing Coronary Angiography[J]. Am J Cardiol, 2020,127:9-15.
[15] Saez-Maleta R, Merino-Merino A, Gundin-Menendez S, et al. sST2 and Galectin-3 genotyping in patients with persistent atrial fibrillation[J]. Mol Biol Rep, 2021,48(2):1601-1606.
[16] Zhang G, Wu Y. Circulating Galectin-3 and atrial fibrillation recurrence after catheter ablation: a meta-analysis[J]. Cardiovasc Ther, 2019,2019:4148129.
[17] Fashanu OE, Norby FL, Aguilar D, et al. Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study[J]. Am Heart J, 2017,192:19-25.
[18] Wang Q, Xu L, Dong Y, et al. Plasma Galectin-3 is associated with progression from paroxysmal to persistent atrial fibrillation[J]. BMC Cardiovasc Disord, 2021,21(1):226.
[19] He M, Zhao WB, Nguyen MN, et al. Association between heart rate variability indices and features of spontaneous ventricular tachyarrhythmias in mice[J]. Clin Exp Pharmacol Physiol, 2020,47(7):1193-1202.
[20] Erdogan O, Karaayvaz E, Erdogan T, et al. A new biomarker that predicts ventricular arrhythmia in patients with ischemic dilated cardiomyopathy[J]: Galectin-3. Rev Port Cardiol (Engl Ed), 2021,40(11):829-835.
[21] Yu L, Ruifrok WP, Meissner M, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis[J]. Circ Hear Fail, 2013,6(1):107-117.
[22] Calvier L, Miana M, Reboul P, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis[J]. Arterioscler Thromb Vasc Biol, 2013,33(1):67-75.
[23] MacKinnon AC, Liu X, Hadoke PW, et al. Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice[J]. Glycobiology, 2013,23(6):654-663.
[24] Pozder Geb Gehlken C, Rogier van der Velde A, Meijers WC, et al. Pectins from various sources inhibit galectin-3-related cardiac fibrosis[J]. Curr Res Transl Med, 2022,70(1):103321.
[25] Varasteh Z, De Rose F, Mohanta S, et al. Imaging atherosclerotic plaques by targeting Galectin-3 and activated macrophages using (89Zr)-DFO- Galectin3-F(ab')2 mAb[J]. Theranostics, 2021,11(4):1864-1876.
[26] Calvier L, Miana M, Reboul P, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis[J]. Arterioscler Thromb Vasc Biol, 2013,33(1):67-75.
[27] Kolatsi-Joannou M, Price KL, Winyard PJ, et al. Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury[J].PLoS ONE, 2011,6(4):e18683.
[28] Martínez-Martínez E, Calvier L, Fernández-Celis A, et al. Galectin-3 Blockade Inhibits Cardiac Inflammation and Fibrosis in Experimental Hyperaldosteronism and Hypertension[J]. Hypertension, 2015,66(4):767-775.
[29] Calvier L, Martinez-Martinez E, Miana M, et al. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries[J]. JACC Heart Fail, 2015,3(1):59-67.